The carcinoembryonic antigen (CEA) is another attractive target in pancreatic cancer that is currently been explored in clinical trials (NCT01723306, NCT00004178 and NCT01212887). This evidence concerns the gene CEACAM5 and familial pancreatic carcinoma.